ACAD
39.28
+0.06
+0.15%
AEMD
3.776
+0.016
+0.4309%
APRI
3.206
+0.316
+10.9446%
ARNA
1.49
0.00
0.00%
ATEC
2.91
+0.02
+0.69%
CNAT
5.25
+0.03
+0.57%
CRXM
0.255
+0.033
+14.968%
CYTX
1.85
-0.04
-2.12%
DXCM
81.89
+0.5
+0.61%
GNMK
10.545
+0.045
+0.429%
HALO
12.61
+0.05
+0.40%
ILMN
163.37
+2.07
+1.28%
INNV
0.17
+0.01
+6.92%
INO
6.96
-0.04
-0.57%
ISCO
1.04
-0.04
-3.70%
ISIS
57.56
0.00
0.00%
LGND
105.71
+0.38
+0.36%
LPTN
2.93
0.00
0.00%
MBVX
3.01
+0.44
+17.12%
MEIP
1.74
+0.02
+1.16%
MNOV
6.11
+0.03
+0.49%
MRTX
6.2
+0.2
+3.33%
MSTX
0.13
+0.001
+0.6966%
NBIX
44.05
+0.9
+2.09%
NUVA
74.22
+0.25
+0.34%
ONCS
1.4
+0.02
+1.45%
ONVO
2.97
+0.08
+2.77%
OREX
4.38
-0.3
-6.41%
OTIC
15.55
+0.5
+3.32%
QDEL
20.89
+0.2
+0.97%
RCPT
231.96
0.00
0.00%
RGLS
1.15
-0.05
-4.17%
RMD
72.27
+0.35
+0.49%
SCIE
0.001
+0.00
+32.00000%
SPHS
2.76
-0.03
-1.08%
SRNE
5.55
-0.07
-1.33%
TROV
2.1
+0.05
+2.44%
VICL
2.26
-0.01
-0.44%
VOLC
18
0.00
0.00%
ZGNX
10.2
-0.25
-2.39%
ACAD
39.28
+0.06
+0.15%
AEMD
3.776
+0.016
+0.4309%
APRI
3.206
+0.316
+10.9446%
ARNA
1.49
0.00
0.00%
ATEC
2.91
+0.02
+0.69%
CNAT
5.25
+0.03
+0.57%
CRXM
0.255
+0.033
+14.968%
CYTX
1.85
-0.04
-2.12%
DXCM
81.89
+0.5
+0.61%
GNMK
10.545
+0.045
+0.429%
HALO
12.61
+0.05
+0.40%
ILMN
163.37
+2.07
+1.28%
INNV
0.17
+0.01
+6.92%
INO
6.96
-0.04
-0.57%
ISCO
1.04
-0.04
-3.70%
ISIS
57.56
0.00
0.00%
LGND
105.71
+0.38
+0.36%
LPTN
2.93
0.00
0.00%
MBVX
3.01
+0.44
+17.12%
MEIP
1.74
+0.02
+1.16%
MNOV
6.11
+0.03
+0.49%
MRTX
6.2
+0.2
+3.33%
MSTX
0.13
+0.001
+0.6966%
NBIX
44.05
+0.9
+2.09%
NUVA
74.22
+0.25
+0.34%
ONCS
1.4
+0.02
+1.45%
ONVO
2.97
+0.08
+2.77%
OREX
4.38
-0.3
-6.41%
OTIC
15.55
+0.5
+3.32%
QDEL
20.89
+0.2
+0.97%
RCPT
231.96
0.00
0.00%
RGLS
1.15
-0.05
-4.17%
RMD
72.27
+0.35
+0.49%
SCIE
0.001
+0.00
+32.00000%
SPHS
2.76
-0.03
-1.08%
SRNE
5.55
-0.07
-1.33%
TROV
2.1
+0.05
+2.44%
VICL
2.26
-0.01
-0.44%
VOLC
18
0.00
0.00%
ZGNX
10.2
-0.25
-2.39%
Home » Archive by Category

Xconomy

With Reverse Merger, Miragen to Go Public, Get $40M Boost From Investors

November 1, 2016 – 5:32 am

For privately held biotechs, IPOs are the most common road to the public markets, but they’re not the only way. Reverse merging with a shell company is an alternate path, and that’s how Miragen…

[[Click headline to continue reading.]]

On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data

November 1, 2016 – 3:55 am

Drugs that treat a form of vision loss known as age related macular degeneration aren’t just big business. They’re also a controversial part of the national debate over high drug prices, and their…

[[Click headline to continue reading.]]

Bio Roundup: Drug Pricing, Cystic Fibrosis Showdown, Myovant & More

October 28, 2016 – 6:25 am

The 2016 election is (thankfully) almost here, and as one biotech analyst noted this week, a possible Democratic victory is to blame for a big October sell-off in biotech stocks. Since Donald Trump’s…

[[Click headline to continue reading.]]

Despite Low Crop Prices, Corporate and VC Agtech Investments Soar

October 27, 2016 – 4:00 am

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. Venture capital firms have…

[[Click headline to continue reading.]]

FDA: Keytruda Now OK For Some Patients With Untreated Lung Cancer

October 24, 2016 – 9:17 pm

The FDA has approved the use of pembrolizumab (Keytruda) for some previously untreated patients with a certain type of lung cancer, the drug’s owner Merck (NYSE: MRK) announced late Monday….

[[Click headline to continue reading.]]

Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo

October 21, 2016 – 3:30 am

If you’re among those frustrated by the lack of talk about health and science in the three presidential debates, this week perhaps brought you a wee consolation prize. The steady drip of hacked…

[[Click headline to continue reading.]]

BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders

October 20, 2016 – 5:55 am

For three years, a group of investors and experienced neuroscience executives have been stealthily advancing one of the more ambitious new startups in neurology, called BlackThorn Therapeutics. Today…

[[Click headline to continue reading.]]

Arterys, GE Healthcare to Roll Out Next-Gen MRI Scans of Heart

October 19, 2016 – 10:09 am

The healthcare tools of the future often start as research projects in academic medical centers, but they may not break out into widespread clinical practice until some sort of logjam gives way to…

[[Click headline to continue reading.]]

All In One Place: A New Immuno-Oncology Trial Resource

October 19, 2016 – 7:00 am

More than 100 years ago, New York bone surgeon William Coley began to suspect that bacterial infections might be improving the outlook for patients also suffering from cancer. The infections were…

[[Click headline to continue reading.]]

The Power of the Cloud for Life Science R&D

October 19, 2016 – 5:43 am

“In the new world, it is not the big fish which eats the small fish, it’s the fast fish which eats the slow fish…” — Klaus Schwab, Founder/Executive Chairman, World…

[[Click headline to continue reading.]]